Objective: The mechanism of Panax notoginseng in treating myocardial fibrosis (MF) was investigated using network pharmacology.
Methods: Effective ingredients and potential targets of Panax notoginseng were screened in relevant databases to construct a compound-target network. Targets of MF were then screened to select common targets and construct a protein-protein interaction network. This was followed by Gene Ontology and pathway enrichment analyses. Molecular docking then verified the results of network analysis.
Results: A total of 14 effective ingredients and 119 potential targets for MF were predicted. Quercetin, beta-sitosterol, and gossypetin were speculated to be the main active ingredients. The mechanism of action may be related to AGE-RAGE, proteoglycans, and IL-17 signaling pathways. Five key targets (IL6, ALB, AKT1, TNF, and VEGFA) may be involved in the treatment of MF using Panax notoginseng.
Conclusions: This study embodies the complex network relationship of multicomponents, multitargets, and multipathways of Panax notoginseng in treating MF and provides a novel method for further research on this herb's mechanism.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975676 | PMC |
| http://dx.doi.org/10.1155/2022/8895950 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Notoginsenoside R1 Attenuates H/R Injury in H9c2 Cells by Maintaining Mitochondrial Homeostasis.
Curr Issues Mol Biol
January 2025
School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Mitochondrial homeostasis is crucial for maintaining cellular energy production and preventing oxidative stress, which is essential for overall cellular function and longevity. Mitochondrial damage and dysfunction often occur concomitantly in myocardial ischemia-reperfusion injury (MIRI). Notoginsenoside R1 (NGR1), a unique saponin from the traditional Chinese medicine Panax notoginseng, has been shown to alleviate MIRI in previous studies, though its precise mechanism remains unclear.
View Article and Find Full Text PDFPathway Elucidation and Key Enzymatic Processes in the Biodegradation of Difenoconazole by A-3.
J Agric Food Chem
January 2025
Key Laboratory of Sustainable Utilization of Panax Notoginseng Resources of Yunnan Province, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, China.
The extensive agricultural use of the fungicide difenoconazole (DIF) and its associated toxicity increasingly damage ecosystems and human health. Thus, an urgent need is to develop environmentally friendly technological approaches capable of effectively removing DIF residues. In this study, strain A-3 was isolated for the first time which can degrade DIF efficiently.
View Article and Find Full Text PDFScreening and Verification of Blood-Activating Effective Component Group of Panax notoginseng Based on Spectrum-Effect Relationships.
Biomed Chromatogr
February 2025
School of Chinese Medica Materia, Beijing University of Chinese Medicine, Beijing, China.
Panax notoginseng (P. notoginseng) is one of the most famous natural medicines and widely used to promote blood circulation in health care. However, the active component group of P.
View Article and Find Full Text PDFPanax Notoginseng Saponins Inhibit Apoptosis and Alleviate Renal Ischemia-Reperfusion Injury Through the ROCK2/NF-κB Pathway.
Mol Biotechnol
January 2025
The First Affiliated Hospital of Hebei North University Address, 12 Changqing Road, Zhangjiakou City, Hebei Province, China.
Renal ischemia-reperfusion injury (RIRI) is a primary cause of acute kidney injury (AKI), frequently resulting in high mortality rates and progression to chronic kidney disease (CKD). This study aimed to investigate the therapeutic potential of total saponins from Panax notoginseng (PNS) in the context of RIRI. Utilizing a murine RIRI model, the efficacy of PNS was evaluated, demonstrating a significant reduction in renal inflammation and cellular pyroptosis.
View Article and Find Full Text PDFSynergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells.
Integr Cancer Ther
January 2025
Seoul Korean Medicine Hospital of Daejeon University, Seoul, Republic of Korea.
In this study, we investigated the synergistic effect of co-administration of osimertinib and HAD-B1 using gefitinib-resistant non-small cell lung cancer cells, HCC827-GR. HAD-B1 is composed of 4 natural drugs, Panax Notoginseng Radix, Panax ginseng C. A.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!